Milrinone
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Milrinone: Alopecia
One-Sentence Summary
Milrinone is an injectable PDE3 inhibitor used for congestive heart failure. The TxGNN model predicts it may be effective for alopecia, but no clinical trials and no publications currently support this direction, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Alopecia |
| TxGNN Prediction Score | 0.9991 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action text is not available in the data compiled for this report. The pharmacology data shows that milrinone acts on phosphodiesterases, mainly PDE3A and PDE3B, with additional recorded activity at PDE2A and PDE5A. PDE3 inhibition raises cyclic AMP (cAMP). In the heart this strengthens contraction, and in vascular smooth muscle it causes vasodilation and lowers preload and afterload.
The link to alopecia is weak and speculative. The only plausible argument is that vasodilation might improve scalp or hair follicle blood flow, similar to the proposed role of minoxidil. Nothing in the data shows milrinone reaching hair follicles or influencing hair growth.
The same prediction run also placed three other hair disorders among the top four results: hypotrichosis simplex of the scalp, congenital hypotrichosis milia and diffuse alopecia areata. None has a credible PDE3/cAMP connection. For alopecia areata, an autoimmune condition, PDE4 inhibition has the better-established rationale. The high score therefore appears to be a computational pattern rather than a pharmacological signal.
Milrinone is also given as an intravenous infusion for acute heart failure, which is a poor fit for a chronic hair condition.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Status |
|---|---|---|
| 02521407 | MILRINONE LACTATE INJECTION USP | Valid (single-ingredient) |
| 02244622 | MILRINONE LACTATE INJECTION, USP | Valid (single-ingredient) |
Safety Considerations
- Contraindication signals (knowledge-graph derived, not label text): Prior-knowledge links flag kidney disease, hypotensive disorder, myocardial infarction, coronary thrombosis, sudden cardiac arrest, heart conduction disease, hypertrophic cardiomyopathy (including familial), pulmonary valve stenosis, hemoglobinopathy and pyoureter. These should be confirmed against the official package insert.
- Drug Interactions (9 records): Five moderate-level interactions are recorded, with amifostine, diatrizoate, anagrelide, ozanimod and procarbazine. The other four records are target-pharmacology entries (PDE2A, PDE3A, PDE3B, PDE5A) rather than interacting drugs.
Package insert warnings and contraindications were not available for this report. Please refer to the Health Canada package insert for the full safety profile.
Conclusion and Next Steps
Decision: Hold
Rationale: The alopecia prediction has a very high model score but no supporting trials, no literature and no clear mechanistic link. The drug’s cardiovascular risks (arrhythmia, hypotension, renal dose adjustment) and its infusion-only form make it an unlikely candidate for a non-life-threatening hair condition.
For context, other predictions for milrinone in the same run have far more support. Congestive heart failure (L2) is effectively an established use. Headache disorder (L4) is supported only by case reports in reversible cerebral vasoconstriction syndrome. If the goal is a productive repurposing direction, these are better places to focus than alopecia.
To proceed, the following is needed:
- Any preclinical or mechanistic evidence that PDE3 inhibition or cAMP elevation affects hair follicle biology
- A plausible non-systemic route, such as a topical formulation, since the available products are injections
- Package insert warnings and contraindications from Health Canada to complete the safety screening
- Detailed mechanism-of-action data (MOA) to support the mechanistic-link analysis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.